Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (241-250 of 775) with videos related to

Pageof 78
Sort By:
Hepatology (Baltimore, Md.)|January 15, 2013
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinomaWolfgang Sieghart, Florian Hucke, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)|May 12, 2012
Common genetic variation in vitamin D metabolism is associated with liver stiffnessFrank Grünhage, Katrin Hochrath, Marcin Krawczyk, et al.
Toxicology Letters|November 6, 2013
Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in miceMin Yang, Anup Ramachandran, Hui-Min Yan, et al.
Journal of Hepatology|April 26, 2024
Assessment of fatigue and its impact in chronic liver diseaseZobair M Younossi, Andreas E Kremer, Mark G Swain, et al.
Alimentary Pharmacology & Therapeutics|May 27, 2024
Portal hypertension and its prognostic implications in patients with Wilson's diseaseLukas Burghart, Peter Ferenci, Oleksandr Petrenko, et al.
Alimentary Pharmacology & Therapeutics|April 9, 2024
Editorial: Recompensation in PBC is good. But is it good enough? Authors' replyBenedikt Silvester Hofer, Lukas Burghart, Emina Halilbasic, et al.
Wiener Klinische Wochenschrift|September 15, 2020
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Emina Halilbasic, Harald Hofer, et al.
Journal of Cellular and Molecular Medicine|January 14, 2022
Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver diseaseAnja Baumann, Dragana Rajcic, Annette Brandt, et al.
Plos One|August 26, 2021
COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospitalKatharina Pomej, Bernhard Scheiner, Lukas Hartl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 26, 2018
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertensionRafael Paternostro, Birgit B Heinisch, Thomas Reiberger, et al.
Pageof 78

Showing results (241-250 of 775) with videos related to

Sort By:
Pageof 78
Hepatology (Baltimore, Md.)|January 15, 2013
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinomaWolfgang Sieghart, Florian Hucke, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)|May 12, 2012
Common genetic variation in vitamin D metabolism is associated with liver stiffnessFrank Grünhage, Katrin Hochrath, Marcin Krawczyk, et al.
Toxicology Letters|November 6, 2013
Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in miceMin Yang, Anup Ramachandran, Hui-Min Yan, et al.
Journal of Hepatology|April 26, 2024
Assessment of fatigue and its impact in chronic liver diseaseZobair M Younossi, Andreas E Kremer, Mark G Swain, et al.
Alimentary Pharmacology & Therapeutics|May 27, 2024
Portal hypertension and its prognostic implications in patients with Wilson's diseaseLukas Burghart, Peter Ferenci, Oleksandr Petrenko, et al.
Alimentary Pharmacology & Therapeutics|April 9, 2024
Editorial: Recompensation in PBC is good. But is it good enough? Authors' replyBenedikt Silvester Hofer, Lukas Burghart, Emina Halilbasic, et al.
Wiener Klinische Wochenschrift|September 15, 2020
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Emina Halilbasic, Harald Hofer, et al.
Journal of Cellular and Molecular Medicine|January 14, 2022
Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver diseaseAnja Baumann, Dragana Rajcic, Annette Brandt, et al.
Plos One|August 26, 2021
COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospitalKatharina Pomej, Bernhard Scheiner, Lukas Hartl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 26, 2018
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertensionRafael Paternostro, Birgit B Heinisch, Thomas Reiberger, et al.
Pageof 78